Evidence map›Paper›PMID 41994936›Full record

ReviewArchiv der Pharmazie2026

Fully Synthetic Non-Carbohydrate Heparin Mimetics-Perspectives for Therapeutic Anticoagulation and Beyond?

Katrin Nekipelov, Vito Ferro, Gerd Bendas

Abstract readReview
In one paragraph

Review in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Katrin NekipelovPharmaceutical Department, University of Bonn, Bonn, Germany.
Vito FerroSchool of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, Australia.
Gerd BendasPharmaceutical Department, University of Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0002-8667-7201

Funding

Deutsche Forschungsgemeinschaft 494832089;GRK 2873
6 · The paper itself

Abstract

Heparin is one of the oldest drugs on the market. Although clinically well established as an anticoagulant for decades, owing to its natural origin and heterogeneous glycosaminoglycan polysaccharide structure, ensuring consistent quality and reproducible biological activity remains challenging. While these facts argue against future applications of heparin in clinical routine, an increasing number of studies reveal additional potential therapeutic applications of heparin beyond its anticoagulant efficacy, that is, as an antiviral strategy or as a multi-targeted approach in oncology. Therefore, heparin appears to be a structural template for pleiotropic compounds. To combine the beneficial pleiotropic properties of heparin with improved reproducibility and safety, fully synthetic heparin mimetic substances have increasingly become a focus of scientific research. These studies enable more detailed structure-activity relationships of heparin in its interaction with proteins or diseases to be elucidated, thereby facilitating the development of novel compounds for potential therapeutic use. This review focuses in particular on fully synthetic non-carbohydrate heparin mimetic polymers with anticoagulant activities, as well as their properties beyond anticoagulation. Advances in the development of such mimetics, especially over the past decade, allow increasingly robust conclusions to be drawn regarding their efficacy and contribute to a deeper understanding of this class of compounds.

Indexed as

AnticoagulantsHeparinAnimalsBiomimetic MaterialsHumansMolecular StructurePolymersStructure-Activity RelationshipAnticoagulantsHeparinPolymersanticoagulationHeparinHeparin mimeticssynthetic polymers

Identifiers

PMID41994936
PMCPMC13088229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.